Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Targeted deletion of PD-1 in myeloid cells induces antitumor immunity.

Strauss L, Mahmoud MAA, Weaver JD, Tijaro-Ovalle NM, Christofides A, Wang Q, Pal R, Yuan M, Asara J, Patsoukis N, Boussiotis VA.

Sci Immunol. 2020 Jan 3;5(43). pii: eaay1863. doi: 10.1126/sciimmunol.aay1863.

PMID:
31901074
2.

Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma.

LeBlanc R, Song K, White D, Christofides A, Doucette S.

Curr Oncol. 2019 Aug;26(4):e581-e594. doi: 10.3747/co.26.5565. Epub 2019 Aug 1.

3.

Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma.

Skrabek P, Assouline S, Christofides A, MacDonald D, Prica A, Sangha R, Matthews BA, Sehn LH.

Curr Oncol. 2019 Aug;26(4):253-265. doi: 10.3747/co.26.5421. Epub 2019 Aug 1. Review.

4.

Evidence for miR-548c-5p regulation of FOXC2 transcription through a distal genomic target site in human podocytes.

Christofides A, Papagregoriou G, Dweep H, Makrides N, Gretz N, Felekkis K, Deltas C.

Cell Mol Life Sci. 2019 Sep 17. doi: 10.1007/s00018-019-03294-z. [Epub ahead of print]

PMID:
31531679
5.

A Canadian guideline on the use of next-generation sequencing in oncology.

Yip S, Christofides A, Banerji S, Downes MR, Izevbaye I, Lo B, MacMillan A, McCuaig J, Stockley T, Yousef GM, Spatz A.

Curr Oncol. 2019 Apr;26(2):e241-e254. doi: 10.3747/co.26.4731. Epub 2019 Apr 1.

6.

Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.

Owen C, Berinstein NL, Christofides A, Sehn LH.

Curr Oncol. 2019 Apr;26(2):e233-e240. doi: 10.3747/co.26.4345. Epub 2019 Apr 1. Review.

7.

A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.

Dent S, Ammendolea C, Christofides A, Edwards S, Incekol D, Pourmirza B, Kfoury S, Poirier B.

Curr Oncol. 2019 Feb;26(1):e70-e80. doi: 10.3747/co.26.4220. Epub 2019 Feb 1. Review.

8.

Fast Temperature-Gradient COLD PCR for the enrichment of the paternally inherited SNPs in cell free fetal DNA; an application to non-invasive prenatal diagnosis of β-thalassaemia.

Byrou S, Makrigiorgos GM, Christofides A, Kallikas I, Papasavva T, Kleanthous M.

PLoS One. 2018 Jul 25;13(7):e0200348. doi: 10.1371/journal.pone.0200348. eCollection 2018.

9.

Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective.

Ionescu DN, Downes MR, Christofides A, Tsao MS.

Curr Oncol. 2018 Jun;25(3):e209-e216. doi: 10.3747/co.25.4031. Epub 2018 Jun 28. Review.

10.

Critical Role of IL-8 Targeting in Gliomas.

Kosmopoulos M, Christofides A, Drekolias D, Zavras PD, Gargalionis AN, Piperi C.

Curr Med Chem. 2018;25(17):1954-1967. doi: 10.2174/0929867325666171129125712. Review.

PMID:
29189120
11.

Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.

Owen C, Christofides A, Johnson N, Lawrence T, MacDonald D, Ward C.

Leuk Lymphoma. 2017 Dec;58(12):2777-2785. doi: 10.1080/10428194.2017.1318439. Epub 2017 May 16. Review.

PMID:
28509580
12.

A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma.

MacDonald D, Crosbie T, Christofides A, Assaily W, Wiernikowski J.

Curr Oncol. 2017 Feb;24(1):33-39. doi: 10.3747/co.24.3470. Epub 2017 Feb 27. Review.

13.

Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

MacDonald D, Prica A, Assouline S, Christofides A, Lawrence T, Sehn LH.

Curr Oncol. 2016 Dec;23(6):407-417. doi: 10.3747/co.23.3405. Epub 2016 Dec 21. Review.

14.

Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.

Christofides A, Karantanos T, Bardhan K, Boussiotis VA.

Oncotarget. 2016 Dec 20;7(51):85624-85640. doi: 10.18632/oncotarget.12928. Review.

15.

Corrigendum: Regulation of T Cell Differentiation and Function by EZH2.

Karantanos T, Christofides A, Bardhan K, Li L, Boussiotis VA.

Front Immunol. 2016 Sep 14;7:346. doi: 10.3389/fimmu.2016.00346. eCollection 2016.

16.

Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.

Isidori A, Christofides A, Visani G.

Leuk Lymphoma. 2016 Nov;57(11):2499-509. doi: 10.1080/10428194.2016.1185785. Epub 2016 May 31. Review.

PMID:
27243412
17.

Prevalence of RhD status and clinical application of non-invasive prenatal determination of fetal RHD in maternal plasma: a 5 year experience in Cyprus.

Papasavva T, Martin P, Legler TJ, Liasides M, Anastasiou G, Christofides A, Christodoulou T, Demetriou S, Kerimis P, Kontos C, Leontiades G, Papapetrou D, Patroclos T, Phylaktou M, Zottis N, Karitzie E, Pavlou E, Kountouris P, Veldhuisen B, van der Schoot E, Kleanthous M.

BMC Res Notes. 2016 Apr 1;9:198. doi: 10.1186/s13104-016-2002-x.

18.

A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia.

Lachance S, Christofides AL, Lee JK, Sehn LH, Ritchie BC, Shustik C, Stewart DA, Toze CL, Haddad E, Vinh DC.

Curr Oncol. 2016 Feb;23(1):42-51. doi: 10.3747/co.23.2810. Epub 2016 Feb 18. Review.

19.

An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT.

Kouroukis CT, Crump M, MacDonald D, Larouche JF, Stewart DA, Johnston J, Sauvageau S, Beausoleil E, Sage P, Dubois SG, Christofides A, Di Clemente S, Sehn L.

Curr Oncol. 2015 Aug;22(4):260-71. doi: 10.3747/co.22.2431.

20.

A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.

Owen C, Bence-Bruckler I, Chamakhi I, Toze C, Assaily W, Christofides A, Robinson S.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):303-13. doi: 10.1016/j.clml.2015.03.002. Epub 2015 Mar 26. Review.

PMID:
25937158
21.

Pathophysiological mechanisms regulated by cytokines in gliomas.

Christofides A, Kosmopoulos M, Piperi C.

Cytokine. 2015 Feb;71(2):377-84. doi: 10.1016/j.cyto.2014.09.008. Epub 2014 Nov 4. Review.

PMID:
25458967
22.

A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults.

Seftel MD, Barnett MJ, Couban S, Leber B, Storring J, Assaily W, Fuerth B, Christofides A, Schuh AC.

Curr Oncol. 2014 Oct;21(5):234-50. doi: 10.3747/co.21.2183.

23.

An unusual place to find a lost needle in laparoscopic surgery.

Al Jaafari F, Christofides AG, Bell CR, Beatty JD.

Ann R Coll Surg Engl. 2014 Sep;96(6):e6-7. doi: 10.1308/003588414X13946184902127.

24.

A Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board.

Kuruvilla J, Assouline S, Hodgson D, MacDonald D, Stewart D, Christofides A, Komolova M, Connors J.

Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):59-74. doi: 10.1016/j.clml.2014.07.015. Epub 2014 Aug 2. Review.

PMID:
25195028
25.

Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.

Couban S, Savoie L, Mourad YA, Leber B, Minden M, Turner R, Palada V, Shehata N, Christofides A, Lachance S.

Curr Oncol. 2014 Apr;21(2):e265-309. doi: 10.3747/co.21.1834.

26.

Osteoprotegerin expression during the micro- and macrometastatic phases of the osteoblastic metastasis in prostate cancer: therapeutic implications.

Pneumaticos SG, Christofides A, Gkioka E, Kalogeropoulos T, Msaouel P, Koutsilieris M.

Expert Opin Ther Targets. 2013 Dec;17(12):1395-403. doi: 10.1517/14728222.2013.834889. Epub 2013 Sep 12. Review.

PMID:
24024908
27.

A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.

Van der Jagt R, Laneuville P, Macdonald D, Stewart D, Christofides A, Sehn LH.

Curr Oncol. 2012 Jun;19(3):160-8. doi: 10.3747/co.19.1064.

28.

Relative bioavailability of iron and folic acid from a new powdered supplement compared to a traditional tablet in pregnant women.

Hartman-Craven B, Christofides A, O'Connor DL, Zlotkin S.

BMC Pregnancy Childbirth. 2009 Jul 27;9:33. doi: 10.1186/1471-2393-9-33.

29.

Low dose 'Sprinkles'-- an innovative approach to treat iron deficiency anemia in infants and young children.

Hirve S, Bhave S, Bavdekar A, Naik S, Pandit A, Schauer C, Christofides A, Hyder Z, Zlotkin S.

Indian Pediatr. 2007 Feb;44(2):91-100.

30.
31.
32.

Acceptability of micronutrient sprinkles: a new food-based approach for delivering iron to First Nations and Inuit children in Northern Canada.

Christofides A, Schauer C, Sharieff W, Zlotkin SH.

Chronic Dis Can. 2005 Fall;26(4):114-20.

PMID:
16390629
33.

Iron deficiency anemia among children: Addressing a global public health problem within a Canadian context.

Christofides A, Schauer C, Zlotkin SH.

Paediatr Child Health. 2005 Dec;10(10):597-601.

34.

Micronutrient sprinkles to control childhood anaemia.

Zlotkin SH, Schauer C, Christofides A, Sharieff W, Tondeur MC, Hyder SM.

PLoS Med. 2005 Jan;2(1):e1. No abstract available.

35.

Controlling iron deficiency anemia through the use of home-fortified complementary foods.

Zlotkin SH, Christofides AL, Hyder SM, Schauer CS, Tondeur MC, Sharieff W.

Indian J Pediatr. 2004 Nov;71(11):1015-9. Review.

PMID:
15572823
36.

Supplemental Content

Loading ...
Support Center